Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices

News Competition Sanctions & Fines

Date: 8th May, 2025 Source: Competition and Markets Authority Country: United Kingdom Original Source

Brief

On December 2024, the Court of Appeal upheld the Competition and Markets Authority's (CMA) finding of excessive pricing by Advanz Pharma in supplying liothyronine tablets to the NHS. The CMA was also successful in reinstating the full penalty of £51.9 million imposed on private equity firm Cinven, bringing the total amount in fines to £99 million.

This content is restricted.

Highlights content goes here...

This content is restricted.

Competition and Markets Authority

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices

Brief

Competition and Markets Authority

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices

Brief

Competition and Markets Authority

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.